帯状疱疹後神経痛に対するコハク酸プレドニゾロンを用いたくも膜下ステロイド治療

  • 黒川 博己
    Department of Anesthesiology and Critical Care Medicine, Hiroshima University Faculty of Medicine
  • 森脇 克行
    Department of Anesthesiology, National Hospital Kure Medical Center
  • 佐伯 昇
    Division of Surgery, Hiroshima Univesity Hospital
  • 楠 真二
    Division of Surgery, Hiroshima Univesity Hospital
  • 河本 昌志
    Department of Anesthesiology and Critical Care Medicine, Hiroshima University Faculty of Medicine
  • 弓削 孟文
    Department of Anesthesiology and Critical Care Medicine, Hiroshima University Faculty of Medicine

書誌事項

タイトル別名
  • Intrathecal prednisolone sodium succinate with lidocaine for intractable postherpetic neuralgia
  • ショウレイ タイジョウホウシンゴ シンケイツウ ニ タイスル コハクサン プレドニゾロン オ モチイタク モ マク カ ステロイド チリョウ リドカイン ヘイヨウ ノ ユウヨウセイ ト モンダイテン

この論文をさがす

説明

Intrathecal injection of prednisolone sodium succinate is approved in Japan for treatment of such diseases as encephalomyelitis, central nervous system leukemia and malignant lymphoma. We gave a total of 16 intrathecal prednisolone sodium succinate injections (each, 40mg dissolved in 2-3ml of 3% lidocaine) to six patients with intractable postherpetic neuralgia, and reviewed the therapeutic utility and complications. The median visual analogue scale pain-intensity score decreased significantly, from 55mm to 35mm, after the treatment (p<0.05). Ephedrine hydrochloride was necessary in 14 of the 16 injections, to treat hypotension. In addition, respiratory depression from a high level of spinal anesthesia and sedation occurred 11 times and required assisted ventilation, while diazepam was given 9 times for treatment and prevention of local anesthetic adverse effects on the central nervous system. We conclude that intrathecal prednisolone sodium succinate injection therapy is useful for intractable postherpetic neuralgia patients, however, side effects caused by the solvent lidocaine occurred frequently. Therefore, we consider it important to perform this method with careful monitoring.

収録刊行物

参考文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ